Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 Visningar
• 07/02/23
0
0
Bädda in
administrator
Prenumeranter
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna